Buy & Sell United Parcel Service Inc (UPS) – United Parcel Service Inc Price Today
Aura AI Summary
Key Stats
- $89.13BMarket Cap
- IndustrialsSector
- -12.17%3M Drawdown
- $111.99BEnterprise Value
- 6.26%Dividend Yield
- 20% Buy | 80% SellTrading Activity
- 137 daysTypical Hold Time
United Parcel Service Inc (UPS) is currently valued at a market capitalization of $89.13B, with an enterprise value of $111.99B. Over the past 52 weeks, United Parcel Service Inc has traded between a low of $82.58 and a high of $120, highlighting its annual price range. Over the past three months, United Parcel Service Inc has recorded a drawdown of -12.17%, reflecting recent price volatility. United Parcel Service Inc offers a dividend yield of 6.26%, with the most recent dividend of $1.64 paid on 18 May 26. On average, investors hold United Parcel Service Inc for approximately 137 days, indicating typical investor behavior on the platform.
About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Most Recent News
Signify unveils strategy to boost focus, performance, and shareholder value by 2029.
Signify announced a new strategy at its 2026 Capital Markets Day to become a more focused and better-performing company by 2029. The plan includes prioritizing growth in connected lighting and consumer segments while optimizing less profitable areas....

EU approves Cenrifki as first drug targeting disability progression in secondary progressive multiple sclerosis without relapses
The European Commission has approved Cenrifki (tolebrutinib) by Sanofi for treating secondary progressive multiple sclerosis (SPMS) without relapses, based on positive phase 3 trial results showing it delays disability progression. This is the first ...

EU approves Sanofi's Cenrifki for secondary progressive multiple sclerosis without relapses
The European Commission has approved Sanofi's Cenrifki (tolebrutinib) as the first medicine targeting disability progression in secondary progressive multiple sclerosis (SPMS) without relapses. Approval is based on positive phase 3 clinical trial res...
